Cargando…

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS

A sensitive and selective ultra‐high performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method for the simultaneous determination of seven oral oncolytics (two PARP inhibitors, i.e. olaparib and niraparib, and five tyrosine kinase inhibitors, i.e. cobimetinib, cabozantinib, dabr...

Descripción completa

Detalles Bibliográficos
Autores principales: Krens, Stefanie D., van der Meulen, Eric, Jansman, Frank G.A., Burger, David M., van Erp, Nielka P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065026/
https://www.ncbi.nlm.nih.gov/pubmed/31758580
http://dx.doi.org/10.1002/bmc.4758
_version_ 1783504983158685696
author Krens, Stefanie D.
van der Meulen, Eric
Jansman, Frank G.A.
Burger, David M.
van Erp, Nielka P.
author_facet Krens, Stefanie D.
van der Meulen, Eric
Jansman, Frank G.A.
Burger, David M.
van Erp, Nielka P.
author_sort Krens, Stefanie D.
collection PubMed
description A sensitive and selective ultra‐high performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method for the simultaneous determination of seven oral oncolytics (two PARP inhibitors, i.e. olaparib and niraparib, and five tyrosine kinase inhibitors, i.e. cobimetinib, cabozantinib, dabrafenib, vemurafenib and regorafenib, plus its active metabolite regorafenib M2) in EDTA plasma was developed and validated. Stable isotope‐labelled internal standards were used for each analyte. A simple protein precipitation method was performed with acetonitrile. The LC–MS/MS system consisted of an Acquity H‐Class UPLC system, coupled to a Xevo TQ‐S micro tandem mass spectrometer. The compounds were separated on a Waters CORTECS UPLC C18 column (2.1 × 50 mm, 1.6 μm particle size) and eluted with a gradient elution system. The ions were detected in the multiple reaction monitoring mode. The method was validated for cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and regorafenib M2 over the ranges 6–1000, 100–5000, 10–4000, 200–2000, 200–20,000, 5000–100,000, 500–10,000 and 500–10,000 μg/L, respectively. Within‐day accuracy values for all analytes ranged from 86.8 to 115.0% with a precision of <10.4%. Between‐day accuracy values ranged between 89.7 and 111.9% with a between‐day precision of <7.4%. The developed method was successfully used for guiding therapy with therapeutic drug monitoring in cancer patients and clinical research programs in our laboratory.
format Online
Article
Text
id pubmed-7065026
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70650262020-03-16 Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS Krens, Stefanie D. van der Meulen, Eric Jansman, Frank G.A. Burger, David M. van Erp, Nielka P. Biomed Chromatogr Research Articles A sensitive and selective ultra‐high performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method for the simultaneous determination of seven oral oncolytics (two PARP inhibitors, i.e. olaparib and niraparib, and five tyrosine kinase inhibitors, i.e. cobimetinib, cabozantinib, dabrafenib, vemurafenib and regorafenib, plus its active metabolite regorafenib M2) in EDTA plasma was developed and validated. Stable isotope‐labelled internal standards were used for each analyte. A simple protein precipitation method was performed with acetonitrile. The LC–MS/MS system consisted of an Acquity H‐Class UPLC system, coupled to a Xevo TQ‐S micro tandem mass spectrometer. The compounds were separated on a Waters CORTECS UPLC C18 column (2.1 × 50 mm, 1.6 μm particle size) and eluted with a gradient elution system. The ions were detected in the multiple reaction monitoring mode. The method was validated for cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and regorafenib M2 over the ranges 6–1000, 100–5000, 10–4000, 200–2000, 200–20,000, 5000–100,000, 500–10,000 and 500–10,000 μg/L, respectively. Within‐day accuracy values for all analytes ranged from 86.8 to 115.0% with a precision of <10.4%. Between‐day accuracy values ranged between 89.7 and 111.9% with a between‐day precision of <7.4%. The developed method was successfully used for guiding therapy with therapeutic drug monitoring in cancer patients and clinical research programs in our laboratory. John Wiley and Sons Inc. 2020-01-13 2020-03 /pmc/articles/PMC7065026/ /pubmed/31758580 http://dx.doi.org/10.1002/bmc.4758 Text en © 2019 The Authors. Biomedical Chromatography published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Krens, Stefanie D.
van der Meulen, Eric
Jansman, Frank G.A.
Burger, David M.
van Erp, Nielka P.
Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
title Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
title_full Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
title_fullStr Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
title_full_unstemmed Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
title_short Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
title_sort quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib m2 in human plasma by uplc–ms/ms
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065026/
https://www.ncbi.nlm.nih.gov/pubmed/31758580
http://dx.doi.org/10.1002/bmc.4758
work_keys_str_mv AT krensstefanied quantificationofcobimetinibcabozantinibdabrafenibniraparibolaparibvemurafenibregorafenibanditsmetaboliteregorafenibm2inhumanplasmabyuplcmsms
AT vandermeuleneric quantificationofcobimetinibcabozantinibdabrafenibniraparibolaparibvemurafenibregorafenibanditsmetaboliteregorafenibm2inhumanplasmabyuplcmsms
AT jansmanfrankga quantificationofcobimetinibcabozantinibdabrafenibniraparibolaparibvemurafenibregorafenibanditsmetaboliteregorafenibm2inhumanplasmabyuplcmsms
AT burgerdavidm quantificationofcobimetinibcabozantinibdabrafenibniraparibolaparibvemurafenibregorafenibanditsmetaboliteregorafenibm2inhumanplasmabyuplcmsms
AT vanerpnielkap quantificationofcobimetinibcabozantinibdabrafenibniraparibolaparibvemurafenibregorafenibanditsmetaboliteregorafenibm2inhumanplasmabyuplcmsms